Today: 1 July 2026
Vanguard’s $505M Strategy Stake Puts Bitcoin-Proxy Stock MSTR Back in Play
20 January 2026
1 min read

Vanguard’s $505M Strategy Stake Puts Bitcoin-Proxy Stock MSTR Back in Play

NEW YORK, Jan 20, 2026, 05:59 EST

  • Vanguard’s U.S. mid-cap index fund reportedly made its initial move into Strategy (MSTR), with a stake valued at about $505 million
  • Strategy shares climbed roughly 1.6% ahead of the open
  • Crypto outlets also highlighted growing Strategy exposure at VanEck alongside new Vanguard-linked purchases through MSTR

Vanguard’s U.S. mid-cap index fund has made its first disclosed purchase of Strategy Inc (MSTR), acquiring around 2.91 million shares valued at approximately $505 million, Odaily Planet Daily reported on Binance Square. Strategy plans to release its fourth-quarter earnings on Feb. 5 and currently holds 687,410 bitcoin, worth about $66.5 billion.

The disclosure is drawing attention since Vanguard ranks among the largest money managers worldwide. The firm reported managing $12 trillion in assets globally as of Nov. 30, 2025, so even a $500 million stake barely registers on its books.

Strategy often acts as a proxy for bitcoin exposure, holding a hefty amount of the cryptocurrency on its balance sheet. This connection drags the stock along with crypto’s risk-on, risk-off moves, despite it trading like a typical U.S.-listed equity.

Strategy shares climbed 1.6% ahead of the open, hitting $173.71 in premarket action.

Another exchange update revealed Vanguard snapped up roughly $68 million in “bitcoin-related assets” via MSTR over the last two weeks, according to an account named The Bitcoin Historian. The report didn’t specify which Vanguard branches made the purchases. Bitget

CoinGape, in a technical note on the stock, highlighted wider institutional interest. VanEck owned roughly 284,000 common shares and recently increased its stake with preferred instruments linked to Strategy’s bitcoin-weighted balance sheet.

Preferred shares, which usually offer fixed dividends, rank higher than common stock when it comes to payouts. They allow investors to maintain exposure but adjust the balance between risk and income for their portfolios.

Vanguard’s mid-cap portfolio may hold the Strategy stake simply because of mechanics. Index funds buy according to their benchmarks and rebalance when market values change, occasionally pushing cautious managers into stocks their clients hadn’t anticipated.

Strategy’s use of leverage, however, works both ways. A steep plunge in bitcoin could quickly damage the company’s balance sheet and drag the stock down, forcing index funds and other holders to sell off shares as their weights adjust.

Investors are focused on the company’s upcoming quarterly results for clues about the bitcoin stash, funding strategies, and buying pace. They’ll also be looking to see if major passive managers view the stock as just another mid-cap holding or if they begin facing tough questions from clients about its presence.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Previous Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT
Next Story

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT

Go toTop